GENSCRIPT BIOTECH CORPORATION Financials Genscript Biotech Corporation
Equities
1548
KYG3825B1059
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.49 HKD | +1.50% |
|
+5.68% | -52.22% |
| 12:47pm | Genscript Biotech CEOs to Receive Shares Under Restricted Share Scheme | MT |
| Jun. 03 | Hong Kong Stocks Rebound Following More than Expected Growth in China’s Manufacturing Sector | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,262 | 2,842 | 9,299 | 6,731 | 5,400 | 2,583 | - | - |
| Enterprise Value (EV) 1 | 4,262 | 2,842 | 8,055 | 5,828 | 3,995 | 1,743 | 1,919 | 1,900 |
| P/E ratio | -43.4 x | -13.5 x | -25.8 x | -29.4 x | -56.1 x | -25.9 x | 47.9 x | 8.24 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.6 x | 7.27 x | 18.2 x | 10.8 x | 6.43 x | 2.06 x | 1.36 x | 0.96 x |
| EV / Revenue | 15.6 x | 7.27 x | 15.8 x | 9.31 x | 4.76 x | 1.39 x | 1.01 x | 0.7 x |
| EV / EBITDA | -42.7 x | -16.4 x | -25.4 x | -15.6 x | -11.9 x | -8.78 x | 30.7 x | 4.97 x |
| EV / FCF | -33.1 x | -10.4 x | -29.4 x | -17.2 x | 13 x | -6.1 x | -19.7 x | -34.7 x |
| FCF Yield | -3.02% | -9.61% | -3.4% | -5.81% | 7.69% | -16.4% | -5.07% | -2.88% |
| Price to Book | - | 3.15 x | 10.5 x | 6.65 x | 3.88 x | 2.04 x | 1.99 x | 1.63 x |
| Nbr of stocks (in thousands) | 1,875,939 | 1,953,283 | 2,101,341 | 2,115,207 | 2,123,163 | 2,125,577 | - | - |
| Reference price 2 | 2.272 | 1.455 | 4.425 | 3.182 | 2.543 | 1.215 | 1.215 | 1.215 |
| Announcement Date | 3/27/20 | 3/26/21 | 3/20/22 | 3/30/23 | 3/10/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 273.4 | 390.8 | 511.1 | 625.7 | 839.5 | 1,251 | 1,893 | 2,698 |
| EBITDA 1 | -99.94 | -173.6 | -317.3 | -372.6 | -337.1 | -198.6 | 62.51 | 382.5 |
| EBIT 1 | -119.1 | -203.9 | -359.7 | -436.8 | -411 | -243.3 | -20.23 | 417.1 |
| Operating Margin | -43.57% | -52.17% | -70.38% | -69.81% | -48.96% | -19.44% | -1.07% | 15.46% |
| Earnings before Tax (EBT) 1 | -113.7 | -281.9 | -496.4 | -431.7 | -351 | -243.5 | 24.67 | 539.8 |
| Net income 1 | -96.91 | -204.9 | -347.9 | -226.9 | -95.48 | -107.5 | 38.45 | 315 |
| Net margin | -35.45% | -52.44% | -68.07% | -36.26% | -11.37% | -8.59% | 2.03% | 11.68% |
| EPS 2 | -0.0523 | -0.1078 | -0.1713 | -0.1082 | -0.0453 | -0.0469 | 0.0254 | 0.1475 |
| Free Cash Flow 1 | -128.6 | -273 | -274.2 | -338.7 | 307 | -285.8 | -97.25 | -54.73 |
| FCF margin | -47.06% | -69.85% | -53.65% | -54.13% | 36.57% | -22.84% | -5.14% | -2.03% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/27/20 | 3/26/21 | 3/20/22 | 3/30/23 | 3/10/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 281.5 | 391.3 | 448.2 | 547.7 | 699.4 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | -220.2 | -190.8 | -125.9 | -177.8 |
| Operating Margin | - | - | - | - | -56.27% | -42.57% | -22.98% | -25.42% |
| Earnings before Tax (EBT) | - | -123.9 | - | -346.2 | - | - | - | - |
| Net income | -113.1 | -91.85 | -91.12 | -256.7 | - | - | - | - |
| Net margin | - | - | - | -91.21% | - | - | - | - |
| EPS 2 | -0.0601 | - | -0.0461 | - | - | -0.000900 | -0.0100 | -0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/30/20 | 3/26/21 | 8/23/21 | 3/20/22 | 9/26/23 | 3/10/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 1,245 | 903 | 1,405 | 840 | 664 | 682 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -129 | -273 | -274 | -339 | 307 | -286 | -97.3 | -54.7 |
| ROE (net income / shareholders' equity) | -22.5% | -31.9% | -18.7% | -16.3% | -8.2% | -9.49% | 1.53% | 16.3% |
| ROA (Net income/ Total Assets) | - | -17.5% | -9.08% | -7.02% | -3.22% | -2.94% | 1.6% | 5.3% |
| Assets 1 | - | 1,168 | 3,833 | 3,232 | 2,967 | 3,653 | 2,403 | 5,940 |
| Book Value Per Share 2 | - | 0.4600 | 0.4200 | 0.4800 | 0.6600 | 0.6000 | 0.6100 | 0.7500 |
| Cash Flow per Share 2 | - | - | -0.0700 | -0.0600 | -0.1400 | -0.0800 | 0.0300 | 0.4700 |
| Capex 1 | - | 122 | 137 | 218 | 104 | 173 | 202 | 239 |
| Capex / Sales | - | 31.19% | 26.89% | 34.91% | 12.39% | 13.86% | 10.67% | 8.86% |
| Announcement Date | 3/27/20 | 3/26/21 | 3/20/22 | 3/30/23 | 3/10/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.215
USD
Average target price
3.204
USD
Spread / Average Target
+163.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.22% | 2.55B | |
| +46.43% | 56.61B | |
| -7.56% | 39.62B | |
| +36.02% | 39.25B | |
| -9.38% | 28.28B | |
| +11.75% | 26.44B | |
| -16.57% | 20.12B | |
| +30.77% | 12.51B | |
| +28.47% | 12.48B | |
| -0.40% | 12.2B |
- Stock Market
- Equities
- 1548 Stock
- Financials Genscript Biotech Corporation
